Form 4: Axogen Sales VP Doris Quackenbush Sells Shares

Axogen, Inc. Sales VP Doris Quackenbush sold 3,878 shares of common stock on May 7, 2026.

Summary

• Doris Quackenbush, Sales VP at Axogen, Inc., executed a sale of 3,878 shares of common stock.
• The shares were sold at a weighted average price of $43.507 per share.
• The transaction occurred on May 7, 2026.
• Following the transaction, the reporting person retains beneficial ownership of 92,416 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a standard regulatory disclosure of an individual executive's personal financial transaction.

Positives

• The reporting person maintains a significant remaining stake of 92,416 shares in the company.

Negatives

• The transaction represents a divestment of equity by a member of the company's sales leadership team.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term stock performance, though it is often related to personal financial planning.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling by executives is common and often pre-planned for tax or liquidity purposes, and does not necessarily reflect a change in the company's fundamental business trajectory.

Comparison to Industry Standards

• Insider transactions are standard regulatory disclosures for publicly traded companies in the medical technology sector.
• The volume of shares sold is relatively small compared to the total holdings of the executive.

Stakeholder Impact

• Minimal impact expected on shareholders as this is a routine disclosure of an individual executive's transaction.

Key Dates

Keywords

Axogen, AXGN, Insider Trading, Form 4, Stock Sale, Doris Quackenbush